We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Lipoxen | LSE:LPX | London | Ordinary Share | GB00B08NWV55 | ORD 0.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 7.875 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
11/2/2011 17:51 | Drewz - you're right of course; invest in AIM and you should know that you are swimming among sharks. But sometimes the rewards are worth the risks and good results can be obtained even as an 'outsider'. | jsbach123 | |
11/2/2011 14:26 | What's the betting that there is news on its way and 'insider dealing' is order of the day once again for those involved in the City. Meanwhile the poor old private investor has to wait for official news release and buy at the higher price or watch from the sidelines. The market in these small cap AIM stocks is bent in favour of city spiv insiders and it stinks. | drewz | |
11/2/2011 10:13 | Nice to see this moving up instead of down for a change. May it continue. | outfly | |
03/2/2011 23:04 | The share is showing some resilience now. Positive news should result in quite a decent move | buywell2 | |
01/2/2011 10:58 | 123asd.........I hope you are right. Price movement on such low volume would point in that direction. Be interesting to see what would happen if there was more buying pressure. | duplicate book | |
01/2/2011 10:48 | dup - look at the LSE thread - some big buyers there have been soaking up shares, to the extent that I believe the MMs are very short of stock. | 123asd | |
01/2/2011 10:31 | Bit of life again this morning and mm's asking over the offer for 40k shares! News in the offing? I can't believe they are short of stock!! | duplicate book | |
27/1/2011 09:53 | "Looby Loo - 15 Jan'11 - 15:10 - 741 of 742 The directors of Lo-Q (AIM: LOQ) and Lipoxen Plc (AIM: LPX) will be presenting: Thursday the 3rd March 2011," That was changed some time back Lipoxen are not presenting at the 3rd March event - they are presenting later in the year. | eternaloptimist | |
27/1/2011 09:17 | alphatrends......... | duplicate book | |
15/1/2011 15:10 | The directors of Lo-Q (AIM: LOQ) and Lipoxen Plc (AIM: LPX) will be presenting: Thursday the 3rd March 2011, Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB The presentations will start at 6:00pm and finish at approx 7:30pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below. This event is suitable for the following: Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists. The event is not suitable for people pursuing commercial opportunities. If you have any problems registering or queries please email events@proactiveinve For more information on the Chesterfield Mayfair Hotel and to take advantage of Proactive's special negotiated rates click here. Lo-Q Company logo Lo-Q (AIM:LOQ) Lo-Q plc is an AIM listed company with active subsidiary companies in the USA and Canada. We design, install and operate systems which allow members of the public to make ride and show reservations when they visit a theme park or other attraction. Our new flagship product, VQ²º²º is a true virtual queuing system for theme parks. Our proprietary hand-held units, called Q-bots, are used in major theme parks around the world. Lipoxen Plc Company logo Lipoxen Plc (AIM:LPX) Lipoxen is a leading biopharmaceutical company operating from the UK that develops high-value, differentiated pharmaceutical products in the fields of protein drugs, vaccines and anti-cancer drugs. | looby loo | |
13/1/2011 22:52 | The sort of RNS I envisage is either a) Lipoxen sign up with a western partner re last RNS or b) Lipoxen sign up with a partner for their 'flu vaccine' technology News from Russia should also be coming within next few months from two possible fronts | buywell2 | |
13/1/2011 22:49 | Chart still looking good Last major sellers that caused the drop have gone If next RNS is a good one then 20p is on again dyor | buywell2 | |
12/1/2011 19:03 | alimo.......that would be nice, seeing as how just recently one or two big sellers have wanted out :o)) | duplicate book | |
12/1/2011 18:40 | Probably a big buyer wants in. | alimo | |
12/1/2011 12:27 | I can't understand why the MM's don't drop the offer to encourage buying. They seem very happy to sit on 11p bid and take all the sells. With such a wide spread, and the walk down in price over the last few trading days, people are less likely to want to buy in. Are they wanting shares on their books for some reason? | duplicate book | |
12/1/2011 08:54 | I should have said nearer 30%. | outfly | |
12/1/2011 08:44 | I wonder why it has dropped 25% in the last few days? | outfly | |
10/1/2011 23:27 | rkhl - I'm curious as to why you think any future fundraising will take place at so low a price; as far as I'm aware there is a good news flow ahead in H1, including news of the Russian tie up, and of course Baxter's involvement with LPX is still developing - "Baxter is one of Lipoxen's most important partners and the Company's third largest shareholder. We are extremely encouraged by the results seen to date [with PSA-Factor VIII]. In light of the strong scientific progress that has been made over the last three years, there is clear potential for both the lead program PSA-Factor VIII but also for broadening this collaboration for other haemophilia drug therapies. Importantly, progressing this PSA-Factor-VIII programme alone through the clinic will trigger additional cash payments to the Company which would significantly advance our objective of reaching the pivotal cash inflection point in our Company's development to convert Lipoxen into a cash-generative enterprise. We look forward to providing a further update on this programme in due course." Scott Maguire, CEO Lipoxen, RNS of 14th June last. In addition there is the imminent appointment of an NED from Baxter. I understand that the Company has been cash-positive for some months recently and that their cash-burn is in any event low by peer standards. I'm not denying that another placing may be necessary before the Company reaches the above mentioned inflection point, but rather questioning why is would necessarily be at so low a figure as you mention, given recent and future developments. | 123asd | |
10/1/2011 15:04 | I have sold my entire holding here (I was hoping that the EPO results would have brought about a higher sp) until the issue of funding becomes clearer for the next 2 years. I am concerned that any placing now will be near the 7p last time, maybe a bit more at around 8-9p but still lower than where we are now. | rkhl | |
07/1/2011 00:51 | Moving averages moving in right direction now Let us hope for positive developments re Flu partner | buywell2 | |
04/1/2011 08:28 | Looking very strong this morning. News soon on the appointment of the Baxter NED to Lipoxen. Perhaps an update on that side of business too? (PSA-FactorVIII) | 123asd | |
23/12/2010 09:17 | Looking for a repeat of two weeks ago where it held support and 20ma and bounced sharply, stop goes just below y/d low around 12p, good risk reward trade imo risking a penny to make 5p, if it breaks y/d low then could revisit 10p so stops in place... | alphatrends | |
23/12/2010 09:08 | One or two buyers coming back in now. May bounce from yesterdays low, so long as the sellers have finished!! | duplicate book | |
22/12/2010 08:51 | And down we go again. | outfly |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions